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Sudden cardiac death (SCD) is a serious public health problem. In the United States, more
than 300,000 people are affected by SCD every year. Signiﬁcantly, sudden deaths represent
20% of the total mortality and 50% of cardiovascular mortality in Western countries. In
addition, SCD constitutes one of the most important unsolved challenges in the practice of
forensic pathology because of the failure to determine the exact cause of sudden death. In
young individuals, SCD is frequently caused by cardiomyopathies and channelopathies, that
have generally an autosomal dominant pattern of inheritance. The impact of genetics and
genetic testing on the clinical management of these diseases is unquestioned. In particular,
genetic tests are an important tool for identifying pre-symptomatic individuals carrying
genetic variant that predisposes them to SCD. High-throughput sequencing technologies
offer novel opportunities to deeper investigate the genetic background underlying these
fatal diseases and to early identify individuals at risk for SCD. In this review, we provide an
overview of the development of Next-Generation Sequencing (NGS) technologies and of
guidelines useful to design an efﬁcient sequencing protocol and to perform an accurate data
analysis. We suggest a ﬂow chart to follow for the set up of a genetic screening protocol
for the prevention of cardiac pathologies, in particular SCD events, in young athletes.
Keywords: cardiomyopathies, channelopathies, sudden cardiac death, Next-Generation Sequencing, personalized
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INTRODUCTION
DNA sequencing technologies have a broad range of applications
in different ﬁelds, including molecular cloning and identiﬁca-
tion of pathogenic genes as well as comparative and evolutionary
studies. During the past 30 years, Sanger sequencing has been
adopted as the primary technology in the “ﬁrst generation” of
sequencers and has been used in the sequencing of the ﬁrst human
genome (Human Genome Project; Liu et al., 2012). At the begin-
ning of the Human Genome Project, the cost estimate for this
“enterprise” was $2.7 billion. In 2005, with the introduction of
Next-Generation Sequencing (NGS), the identical procedure was
performed for approximately $1.5 million (Wheeler et al., 2008;
Liu et al., 2012). A further decrease in the costs of sequencing was
occurred after 2005, and the NGS technology will become widely
accessible.
In recent years, NGS has been applied to comprehensively
study several Mendelian monogenic disorders as well as com-
plex diseases including cancer (Navin and Hicks, 2011) and
cardiac diseases (Fokstuen et al., 2014). For these multifactorial
diseases, a very important advantage of NGS is the possibil-
ity of testing many genes in a relatively short time and with
low cost.
Sudden cardiac death (SCD), commonly deﬁned as a nat-
ural death from unexplained cardiac causes, is an important
social and medical issue (Brion et al., 2010). Interestingly, young
athletes are among the categories mostly affected by SCD. In
fact, adrenergic stress during competitive sports is a commonly
accepted trigger for arrhythmias and SCD, in the presence of
an underlying inherited cardiac disease such as cardiomyopathy,
primary arrhythmia syndrome or vascular diseases (Corrado et al.,
2005). So, great attention has been focused on a molecular anal-
ysis of cardiac channelopathies and cardiomyopathies that would
allow an early diagnosis and prevention of SCD in a signiﬁcant
percentage of young individuals (Brion et al., 2010).
NGS PROTOCOL DESIGN
To establish a NGS diagnostic protocol, we must ﬁrst perform
a validation phase to verify that all of the mutations previously
found in a group of individuals analyzed with Sanger sequencing
are also detectable with the new sequencing technique. After this
phase, we could continue with an application phase performed on
individuals who were not previously analyzed.
Novel variants identiﬁed by NGS must be conﬁrmed by Sanger
sequencing to evaluate the reproducibility of the NGS approach.
Reproducibility, in a NGS protocol, is intended as conﬁrmation of
the results using a traditional Sanger method. If a speciﬁc variant
revealed by NGS sequencing is not found with Sanger sequencing,
it is not accepted.
An important step of the entire NGS protocol is DNA isolation.
This step in fact, requires the use of a uniform method to guaran-
tee an equal and standardized quality of genomic DNA. Once the
DNA is obtained, the next step is to generate a library by pooling
different DNA samples. Each individual sample, inside the DNA
pool, must be identiﬁable during the data analysis after ligation
with a barcode (Dorn et al., 2013). The use of the barcode is one
of the strengths of the NGS protocol; in fact, a barcode allows
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the analysis of more patients in the same run cycle, yielding lower
analysis costs, and improving clinical response times. The ligation
of DNA with barcodes is a very critical step, and great atten-
tion is devoted to not exchanging the samples to avoid erroneous
results.
Next-Generation Sequencing technologies are suitable for a
wide range of study designs but there are some important points
to consider: the number of individuals to study, the number
of genes to be analyzed and the choice of the sequencing plat-
form. However, for small cohorts, the signiﬁcance of a NGS study
increases if the cohort consists of a homogenous group of individ-
uals (Arad et al., 2005). Another important factor is the number
of genes to analyze, particularly for multifactorial pathologies
caused by variations in more than one gene. The simultaneous
study of a large number of genes makes it possible to under-
line all of the mutations present in one patient and to analyze
the possible correlation between these variants and the pathol-
ogy. This approach is very expensive and requires long analysis
times, which comprise critical points for a diagnostic genetic
test. For a molecular diagnosis, we consider useful to focus on
a limited and selected group of genes considered to be associated
with the pathology under study (Amati and Morini, unpublished
data).
In recent years, several platforms for NGS have been developed;
their main characteristics are summarized in Table 1 (modiﬁed
from Liu et al., 2012; Li et al., 2014).
NGS GUIDELINES FOR DIAGNOSTIC TESTS
A diagnostic test is a medical test performed to aid in the diag-
nosis or detection of a disease. A genetic diagnostic test must be
very speciﬁc and accurate to explain the phenotype of a patient or
to indicate the risk of developing a speciﬁc disease. A diagnostic
test should be carried out by specialized laboratories that produce
results in agreement with the quality and competence standard
for medical laboratories (ISO 15189 or comparable). In general,
a genetic test is performed on a biological sample (commonly a
blood sample) of a subject (patient or proband) and the gene/s of
interest are sequenced to search mutations. Before sample collec-
tion, it is mandatory to obtain informed consent from the patient.
Informed consent is deﬁned as a legal document to ensure that
the patient is aware of all the potential risks and costs involved
in a treatment or procedure. Moreover, an informed consent
informs the patient regarding the nature of the treatment, pos-
sible alternative treatments and potential risks and beneﬁts of the
treatment.
As NGS has been developed as a tool for research applications,
it shows an enormous potential application in genetic diagnosis,
such as to promote genetic tests for hereditary and congeni-
tal disorders (Sikkema-Raddatz et al., 2013). There are different
categories of genetic testing based on NGS technologies, as fol-
lows: whole exome sequencing (WES), whole genome sequencing
(WGS), and Targeted or Panel NGS testing. To select one of these
approaches, the ﬁnality, sensitivity and probability of ﬁnding
unknown variants or variants with an uncertain signiﬁcance as
well as the data storage must be considered.
For the development of a diagnostic NGS test, design and val-
idation are essential steps. Design indicates selecting the genes
to add to the NGS panel; this step is important because it
is not useful to select genes without clear evidence of a dis-
ease association (Rehm et al., 2013). It is important to create
the so-called “core disease gene lists” that include all of the
genes that deﬁnitely contribute to the disease. Test validation
is a fundamental phase aimed to verify that some parame-
ters, such as the sequencing quality, sensitivity, and repro-
ducibility, are close to the referring parameters (Rehm et al.,
2013).
TheNGSdata analysis produces a complete report that includes
the following ﬁles: FASTQ (base calls of all the reads produced
and the quality score of each base); BAM (the alignment of
the reads over the reference genome); Variant Call File (VCF;
the chromosomal position, name, and reference genome of each
variant).
Table 1 |The main characteristics of the most common Next-Generation Sequencing (NGS) platforms (modified from Liu et al., 2012; Li et al.,
2014).
Sequencers 454 GS FLX (Roche) HiSeq 2000 (Illumina) SOLiDv4 (Applied Biosystems) Ion torrent (LifeTechnologies)
Methods Pyrosequencing Sequencing by synthesis Sequencing by ligation Ion semiconductor
Read length 700 bp 50–250 bp 35–50 bp 400 bp
Accuracy* Q > 30 20 < Q > 30 Q > 30 Q20
Reads per run 1 million Up to 3 billion 1.2–1.4 billion Up to 80 million
Time per run 24 h 1–10 days 1–2 weeks 2 h
Cost per 1 million bases $10 $0.05 to $0.15 $0.13 $1
Advantages Read length High throughput Low cost per base Less expensive equipment
Fast Accuracy Fast
Disadvantages Runs expensive Expensive Slower method Homopolymer errors
Homopolymer errors High concentrations of DNA Palindromic sequences errors
Low throughput Short reads Short read
*The values of accuracy have been converted in a Q score value (Ewing and Green, 1998) and refer to the optimal experimental conditions for each NGS platform.
Q score is the measure of base calling accuracy (Ewing and Green, 1998). Low Q values (Q10) can lead to increase false-positive variant calls.
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The amount of data found using a NGS protocol is broad and it
is very important to analyze and classify the variants properly and
to compare themwith the international databases of identiﬁed and
validated variants (i.e., the OMIM1 or the HGMD2). The main
criteria for the identiﬁcation of a nucleotide variant are a read
coverage (the bases are aligned to a speciﬁc nucleotide position)
of≥30-fold and a read percentage (the fraction of bases that differ
from the reference sequence) of ≥20 (Voelkerding et al., 2010). In
general, a nucleotide variant with an allele frequency<0.2 should
be considered as a homozygous reference (WT, wild type); allele
frequencies between 0.2 and 0.8 as heterozygous; variants with
allele frequencies >0.8 must be considered a homozygous muta-
tion (MUT). Variant annotation is a crucial step in the analysis
of NGS data. Variant analysis could be performed using several
on-line programs; one of the most commonly used programs
is ANNOVAR3. However, a manual review of reads through a
speciﬁc browser (i.e., the IGV Browser of the Broad Institute;
Robinson et al., 2011; Thorvaldsdóttir et al., 2013) is required to
check the alignment quality and homogeneous coverage of the
region in question. In fact, regions with repeated sequences, inser-
tions and deletions might be underestimated in an automatic
report obtained by on-line tools. A precise description of each
variant is very important, according to the recommendation of
the Human Genome Variation Society (HGVS), and inclusion of
the genomic coordinates (chr11: g 19207841) for each variant is
highly recommended. For information on whether a novel vari-
ant is common, it is important to compare the variant with the
single nucleotide polymorphism (SNP) Database4. If a nucleotide
variant is not reported in the main mutation databases (i.e., the
OMIM or HGMD), it might be in silico analyzed using the on-line
tool, PolyPhen-25. This software predicts the possible effect of an
amino acid substitution on the structure and function of a human
protein using straightforward physical and comparative consider-
ations. In addition, it is possible to verify the conservation of the
amino acid variant among the species using the ClustalW2 web-
site6. After these in silico evaluations, it is worthwhile to study the
possible functional effect of the nucleotide variant.
Variants are classiﬁed in ﬁve categories: pathogenic, likely
pathogenic, unclassiﬁed (UVs), likely benign and benign variants.
A problematic aspect of a NGS diagnostic test is the possibility
of detecting unsolicited and secondary ﬁndings (so called inci-
dental ﬁndings, IF). It is necessary for laboratories to have a
deﬁned statement for including or not including IF in the ﬁnal
report, in accordance with ethical committees. Reports on the
NGS results should follow the general principles of clinical genetic
reporting (Claustres et al., 2014) and be in agreement with inter-
national diagnostic standards, ISO 15189, and with professional
guidelines such as those issued by the Clinical Molecular Genetics
Society (CMGS) in the UK (Treacy and Robinson, 2013), by the
1http://www.ncbi.nlm.nih.gov/omim
2http://www.hgmd.cf.ac.uk/ac/index.php
3http://www.openbioinformatics.org/annovar/
4http://www.ncbi.nlm.nih.gov/snp
5http://genetics.bwh.harvard.edu/pph2/
6http://www.ebi.ac.uk/Tools/msa/clustalw2/
Human Genetics Society of Australasia7 and by the Swiss Society
of Medical Genetics8.
A report must be clear, succinct and interpretable by a non-
expert; however, it must contain sufﬁcient data for understanding
which genes were investigated and which NGS protocol was
used (i.e., information regarding the kits, the NGS platforms or
the pipeline versions). A report should summarize the patient’s
clinical history and diagnosis as well as the variants identiﬁed.
It is essential that the report mention whether the pathogenic
variants have been conﬁrmed by another independent method
(Sanger). All the limitations of the diagnostics test should be
listed in the report. Among these limitations are repetitive
sequences, pseudogenes, homologous regions, the GC content,
transversions, or inversions that could not be detected and/or are
disregarded.
For polygenic or multifactorial pathologies in which more
genes are involved, such as cardiomyopathies, NGS analysis could
produce a signiﬁcant increase in the diagnostic yield. A“diagnostic
yield” is deﬁned as the probability that a disease-causing variant is
identiﬁed and amolecular diagnosis could bemade,with the likeli-
hood that a test would provide the information needed to establish
a diagnosis (Weiss et al., 2013). The “diagnostic yield” might be a
good instrument for measuring the efﬁciency of a genetic test.
NGS FOR DIAGNOSIS OF HEREDITARY CARDIAC DEFECTS
Before starting a NGS study, it is important to deﬁne the sequenc-
ing approach. It is possible to analyze WES and/or WGS. WGS
allows observation of all the nucleotide variations in the cod-
ing and in non-coding regions while WES identiﬁes variations
in all of the coding regions and appears to be a promising
option for the study of rare inherited disorders caused by muta-
tions in protein-coding sequences (Dorn et al., 2013). Even if
the cost per base is the same, it clear that the cost of WGS is
higher than of WES because the amount of bases to sequence
is higher; the high costs of the WGS procedure often limit its
application.
If the genomic region and/or the gene responsible for one dis-
ease are known, target resequencing is an optimal alternative.
Targeted NGS tests offer the best solution for the genetic screening
of complex diseases, including inherited cardiac diseases, in which
different mutations in a large number of genes are involved.
Next-Generation Sequencing platforms have peculiar char-
acteristics (Table 1). An important feature is accuracy that
refers to the correctness of the sequences, that is base qual-
ity, mapping quality, duplicated reads, GC content, strand
bias, presence of repetitive sequences and existence of pseu-
dogenes. A measure of accuracy is the miscalling of bases
(mismatches) that can cause substantial trouble for example
for the identiﬁcation of SNPs. A recent sequencing study on
several NGS platforms shows that the SOLiD and the Roche
454 platforms provide high-quality sequences, while the call-
ing accuracy of Illumina and Ion PGM sequencing platforms
are slightly lower (Li et al., 2014). The choice between several
7https://www.hgsa.org.au/hgsanews/guidelines-for-implementation-of-massively-
parallel-sequencing
8http://www.sgmg.ch/user_ﬁles/images/SGMG_Reporting_Guidelines.pdf
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platforms depends on the aim and the type of study being
performed.
Different NGS platforms have been used for the molecular
genetic screening of inherited cardiac conditions. Li et al. (2013)
use two different platforms, MiSeq (Illumina, San Diego, CA,
USA), and Ion Torrent PGM (Life Technologies Ldt, Paisley,
UK), to investigate six genes (KCNQ1, KCNH2, SCN5A, KCNE1,
KCNE2, RYR2) associated with inherited arrhythmia syndromes.
Ion PGM is less expensive and fast, whereas MiSeq has a lower
run time and higher capacity. In any case, both platforms are valid
instruments for a molecular diagnosis of inherited cardiac diseases
because they are faster, less expensive and more comprehensive
than traditional genetic diagnostic tests.
A recent diagnostic protocol based on Ion Torrent PGM was
performed by Millat et al. (2014). A cohort of patients, pre-
viously studied by HRM/sequencing, was used to validate an
Ion chip panel designed to identify mutations in the follow-
ing genes: MYH7, MYBPC3, MYL2, LMNA, SCN5A, TNNT2,
TNNI3 and TPM1. All of the substitutions previously found in
the MYBPC3 gene were conﬁrmed whereas some indels were not
identiﬁed by NGS analysis. Most of these indels were located in the
homopolymer regions (long poly A/T regions could cause prob-
lems in DNA sequencing reactions because of “slippage”); this
limit is present in other NGS platforms (such as 454Roche) but
the accuracy of these NGS platforms doesn’t really suffer from it
(Table 1).
Meder et al. (2011), used another NGS approach (TargetSeq)
and SOLiD platform (Applied Biosystem, Carlsbad, CA, USA)
for the analysis of 10 patients with cardiomyopathies (HCM and
DCM). They found mutations in the MYBPC3,MYH7 and LMNA
genes as well as novel variants. To conﬁrm the speciﬁcity of their
results, they selected 50 of these new variants and conﬁrmed their
existence by the Sanger method.
All these data demonstrated that the application of NGS,which
allowed investigators to analyze more patients and more genes in
shorter amounts of time, has been successful for the molecular
diagnosis of hereditary cardiac defects.
NGS: A PROMISING TOOL FOR THE DIAGNOSIS OF SCD
The published data regarding the NGS method and diagnosis of
SCD are limited; results from previous studies are very interest-
ing, and they emphasize that NGS could be a useful investigative
method for clarifying the role of pathogenetic variants in the risk
of developing SCD (Campuzano et al., 2014; Hertz et al., 2014). A
recent paper estimated the frequency of pathogenetic variants in
34 genes related to SCD in forensic patients and in patients with
channelopathies; the conclusion of this work is that NGS could be
considered an important tool for genetic screening of SCD (Hertz
et al., 2014). Another study was conducted to validate the SOLiD
System with the aim to analyze 28 genes known to be associated
with inherited arrhythmogenic disorders and, therefore, with SCD
(Brion et al., 2014).
These studies showed that NGS allows accurate detection of
many variants using a rapid and less expensive method and
it could be a promising diagnostic tool for cardiomyopathies,
channelopathies and SCD.
NGS TEST FOR IDENTIFICATION OF ATHLETES AT RISK
OF SCD
A close collaboration between clinicians and geneticists is
very important for a comprehensive genetic analysis. This
FIGURE 1 | Flow chart of genetic screening for athletes with suspected
cardiac diseases.The left side shows the diagnostic protocol to follow in
cases in which there is a positive family history for cardiac hereditary disease
whereas the right side presents the cases in which there is no family history
of cardiac hereditary disease and the athlete shows cardiac abnormalities on
an ECG or echocardiography.
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collaboration includes the mutual exchange of clinical and lab-
oratory information to explicate the complexity of the pro-
cess of genomic variant interpretation. Family history and
patient symptoms could direct the investigators in the selec-
tion of the study, which would reduce the waiting time
for patients. Genetic testing must be developed in medical
laboratories inwhich genetic counseling andmedicalmanagement
of patients and relatives with inherited pathologies could be
performed. These basic principles are applicable to genetic
screening in asymptomatic patients including high-level ath-
letes at risk of SCD. In this case, two situations are possible
(Figure 1).
The ﬁrst situation is found in cases in which there is a family
history of cardiac hereditary disease and in which one muta-
tion is identiﬁed in the athlete’s family. In these cases, genetic
testing could be proposed to the athlete to search for the spe-
ciﬁc mutation identiﬁed in his/her family. If this mutation is
identiﬁed in the athlete it is possible to stop here. However, if
there is the suspect that more than one gene may be involved,
it is necessary to use a massive approach by NGS. The sec-
ond situation, which is the most common, is found in cases
in which there is no family history of hereditary cardiac dis-
ease but the athlete shows cardiac abnormalities on an ECG or
echocardiography. In these cases, a genetic test could be pro-
posed directly to the athlete; the test must analyze the main
genes associated with hereditary cardiac defects using an NGS
approach.
In both situations, it is important that the molecular labo-
ratory for the genetic testing be equipped to develop functional
studies to verify all the variants identiﬁed in order to evaluate the
pathological effect of these ones.
The test results could be used for an individual’s medical
treatment and to identify other at-risk family members.
CONCLUSION
Next-Generation Sequencing offers novel opportunities to study
and diagnose complex and multifactorial diseases; however,
the economic costs of these analyses remain too high to con-
duct NGS on the general population. In the future, a reduc-
tion of NGS costs would ensure that this diagnostic proce-
dure is universally accessible. An essential direction for the
study of cardiac/cardiovascular pathology would be to use addi-
tional approaches, including proteomics and systems biology,
to enable researchers to ﬁlter and combine genetic data for
a more complete overview of these complex diseases. Until
then, strong integration and collaboration between clinicians
and molecular biologists/geneticists are necessary for personal-
ized, careful screening and counseling for individuals at risk
for SCD.
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